Procyanidin C1 ameliorates aging-related skin fibrosis through targeting EGFR to inhibit TGFβ/SMAD pathway.

Jun-Han Wang, Min Li, Peng-Fei Xie, Jia-Yao Si, Zhen-Jie Feng, Chuan-Feng Tang, Jian-Mei Li

School of Food Science and Pharmaceutical Engineering, Nanjing Normal University, Nanjing 210023, China.School of Food Science and Pharmaceutical Engineering, Nanjing Normal University, Nanjing 210023, China. · pubmed

Paper

Abstract

Aging-related skin fibrosis (SF) is a complex condition with limited treatment options. Procyanidin C1 (PCC1), a natural polyphenolic compound with demonstrated senolytic activity, has emerged as a potential therapeutic agent for fibrotic disorders through its selective elimination of senescent cells. However, its therapeutic efficacy and mechanisms in aging-related SF remain unclear.

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

Procyanidin C1 can ameliorate aging-related skin fibrosis by targeting EGFR to inhibit the TGFβ/SMAD pathway. The paper addresses a potential therapeutic approach to a condition associated with aging, focusing on mechanisms that may contribute to the underlying processes of aging rather than merely treating symptoms.

Author of this paper? Send a correction.